Memantine/donepezil
Medication
From Wikipedia, the free encyclopedia
Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type.[1] It contains memantine hydrochloride (it acts as an NMDA receptor antagonist, among various other types of targets like 5-HT3 receptor, Nicotinic acetylcholine receptor, and Sigma-1 receptor) and donepezil hydrochloride, which is an acetylcholinesterase inhibitor.[1] It is taken by mouth.[1]
Trade namesNamzaric
| Combination of | |
|---|---|
| Memantine | NMDA receptor antagonist |
| Donepezil | Acetylcholinesterase inhibitor |
| Clinical data | |
| Trade names | Namzaric |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Memantine/donepezil was approved for medical use in the United States in 2014.[3]
